Articles

Melphalan 140 mg/m2 or 200 mg/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party

Department of Medicine, Imperial College London, UK
Department of Biology, Tor Vergata University of Rome, Italy
Department of Biology, Tor Vergata University of Rome, Italy
EBMT Data Office, Leiden, the Netherlands
Institut Paoli Calmettes, Marseille, France
Nottingham University, UK
Department of Medicine, Imperial College London, UK
Charles University Hospital, Prague, Czech Republic
St. James’s Hospital, Trinity College Dublin, Ireland
Heinrich Heine Universität, Düsseldorf, Germany
Umeå University Hospital, Sweden
Skåne University Hospital, Lund, Sweden
University of Cologne, Germany
CHU Nantes, France
Kuopio University Hospital, Finland
George Papanicolaou General Hospital, Thessaloniki, Greece
CHU de Lille, LIRIC, INSERM U995, France
Fundeni Clinical Institute, Bucharest, Romania
Radboud University Medical Centre, Nijmegen, the Netherlands
Medical University, Warsaw, Poland
University Hospital Brno, Czech Republic
University of Heidelberg, Germany
Queens University of Belfast, Northern Ireland
Hôpital Saint-Antoine, Paris, France
University Hospital Hamburg-Eppendorf, Hamburg, Germany
Vol. 103 No. 3 (2018): March, 2018 https://doi.org/10.3324/haematol.2017.181339